An investigation of the antidepressant efficacy and safety of an AMPAkine (Org 24448) [farampator] in major depressive disorder, a double-blind, placebo-controlled, randomized study.

Trial Profile

An investigation of the antidepressant efficacy and safety of an AMPAkine (Org 24448) [farampator] in major depressive disorder, a double-blind, placebo-controlled, randomized study.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2012

At a glance

  • Drugs Farampator (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jul 2012 Actual patient number (9) added as reported by ClinicalTrials.gov record.
    • 05 Jul 2012 Actual end date changed from Dec 2008 to Feb 2007 as reported by ClinicalTrials.gov record.
    • 05 Jul 2012 Primary endpoint added as Montgomery-Asberg-Depression-Rating-Scale as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top